HUAREN MEDICAL TECHNOLOGY
NEWS
Company News
19
2023-12
医学科技创新与医学教育进步显著 为我国卫生健康事业发展提供有力保障
在国家卫健委8月25日举行的“一切为了人民健康——我们这十年”系列发布会上，国家卫健委新闻发言人胡强强指出，科学技术是第一生产力。党的十八大以来，我国医学科技创新与医学教育工作取得了显著进步，为国家卫生健康事业发展提供了有力保障。
View More14
2023-12
在医疗器械的动物研究过程中，动物体内测试通常提供医疗器械如何与生物系统相互作用的初步评估，包括器械的生理、病理和毒理学反应，以及生物系统如何影响器械。通常进行动物研究以支持医疗器械上市前申请。
View More21
2023-11
Monsoon Chairman and his team were invited to participate in the 3rd Zhou Shang Conference 2023
From 15th November to 16th November 2023, the 3rd Zhou Shang Conference was held in Zhoukou City, Henan Province. Ji Feng, Chairman of Guangxi Huaren Medical Science and Technology Group, Yang Dengfeng, Technical Director, Xiao Kai and He Wengtan, Deputy General Managers of subsidiaries, attended the meeting.
View More19
2023-09
On September 14, Professor Wan Qi, Director of Neural Regeneration and Rehabilitation Research Institute of Qingdao University, visited Huaren Medical Science and Technology Group, accompanied by Chairman of Huaren Medical Science and Technology Group, Mr. Ji Feng, President Zeng Yong, and Director of Animal Centre, Mr. Wei Zhumei, and had a discussion on in-depth cooperation between industry, academia and research. Zhang Pengfei, project supervisor of the Group's Animal Experiment Department, Huang Xiaojiao, technical supervisor, and Pan Mengxian, topic leader, attended the discussion.
View More11
2023-09
Cell culture is the most basic operation for cell experiments. Through cell culture, we can obtain a large number of cells, which can be used for further research on cell function and signalling pathways, so the quality of cell culture will directly affect the subsequent cell experiments and the accuracy of the results.
View More11
2023-09
An active targeting approach for the treatment of osteosarcoma with nanodelivery systems
Osteosarcoma is the most common in situ tumour of bone, accounting for approximately 35% of bone malignancies. The main symptoms of patients with osteosarcoma include restricted mobility, swelling, severe pain, and pathological fracture, and approximately 10-20% of patients have metastases at the time of their initial consultation. Conventional treatment includes early surgical resection and adjuvant chemotherapy, but a larger proportion of patients still respond poorly to treatment. The current first-line chemotherapeutic agents include adriamycin, cisplatin and methotrexate, which synergistically exert anti-tumour effects through different mechanisms of action, but due to the lack of selectivity of these agents and more pronounced systemic toxicity when applied in high doses, new therapeutic approaches need to be explored.
View MoreSUBSCRIPTION INFORMATION
We will send you real-time information regularly!
Guangxi Huaren Medical Technology Group Co., Ltd.
Tel: 400-138-8669/ 0771-611-0603
Address: 15th Floor, Building A, Biyuan Center, Wuxiang New District, Nanning City, China (Guangxi) Pilot Free Trade Zone
Huaren Medical Technology
Huaren Medical Research
Hua Ren Cell said